Haichuang Pharmaceutical announced that recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by China's State Drug Administration, agreeing to conduct phase III clinical trials for prostate cancer with deuterium enzalutamide softgels. Deuterium enzalutamide softgels are a class 1 new drug independently developed by the company. It is a second-generation androgen receptor inhibitor and has received major scientific and technological support from “National Major New Drug Creation”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.